Journal
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 24, Issue 10, Pages 481-487Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tem.2013.06.002
Keywords
AMPK; aspirin; salicylate; inflammation; diabetes; cancer
Categories
Funding
- Canada Research Chair in Metabolism and Obesity
- Canadian Institutes of Health Research
- Canadian Diabetes Association
- Wellcome Trust
- Cancer Research UK
- AstraZeneca
- Boehringer-Ingelheim
- GlaxoSmithKline
- Merck KgaA
- Janssen Pharmaceutica
- Pfizer
- Cancer Research UK [15101] Funding Source: researchfish
Ask authors/readers for more resources
Salicylates are among the oldest medicinal compounds known to humans, and have been used to reduce fever, pain, and inflammation. The major oral salicylates are aspirin and salsalate, both of which are rapidly metabolized to salicylate in vivo. Owing to its acetyl group, aspirin irreversibly inhibits cyclo-oxygenases and thus blocks platelet aggregation, whereas salsalate has been used for treatment of inflammatory diseases such as rheumatoid arthritis. Recently, beneficial effects of salicylates in type 2 diabetes and cancer have been proposed. This has led to renewed interest in understanding how these simple molecules have such diverse and multifaceted effects. Here we discuss the idea that AMP-activated protein kinase (AMPK) might mediate some effects of salicylate-based drugs, particularly by modulating cellular metabolism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available